Published • loading... • Updated
AbbVie (ABBV) Gets $260 Price Target Upgrades Amid Growing Valuation Worries
Summary by Blockonomi
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
AbbVie (ABBV) Gets $260 Price Target Upgrades Amid Growing Valuation Worries
Key Takeaways 32 Wall Street firms give AbbVie an average brokerage score of 1.61 (positioned between Strong Buy and Buy), including 21 Strong Buy recommendations Citi and UBS both increased ABBV price targets from $230 to $260 Both investment banks keep Neutral ratings despite higher price objectives Zacks assigns ABBV a Rank #4 (Sell), noting consensus EPS projections for the year declined 0.6% to $14.23 GuruFocus indicates ABBV trades approx…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
